抗凝药选择对全膝关节置换术后手法松解、血肿及静脉血栓事件的影响
本研究基于大型全国数据库回顾性分析462,869例初次全膝关节置换术患者,比较阿司匹林与华法林、Xa因子抑制剂及低分子肝素对术后90天内手法松解(MUA)和血肿形成率的影响。结果显示,与阿司匹林相比,更强效抗凝药均显著增加MUA和血肿风险,且不增加血栓风险优势。
要点
- 与阿司匹林相比,Xa因子抑制剂、华法林和低分子肝素均显著增加术后90天内MUA风险。
- 低分子肝素、间接Xa因子抑制剂、直接Xa因子抑制剂和华法林均显著增加血肿形成风险。
- 全膝关节置换术后用阿司匹林预防深静脉血栓不增加血栓风险,且MUA和血肿风险更低。
核心结论
- 全膝关节置换术后使用阿司匹林预防深静脉血栓,与更强效抗凝药相比,显著降低MUA和血肿形成风险,且不增加血栓风险。
研究设计与样本
- 回顾性队列研究,查询大型全国数据库纳入初次全膝关节置换术患者,纳入术前3天至术后5天内填写抗凝药处方者,排除多药或无抗凝药处方者,最终分析462,869例。
主要发现
- 接受直接Xa因子抑制剂者MUA风险OR 1.38(95%CI 1.32–1.43),间接Xa因子抑制剂OR 1.33(95%CI 1.19–1.48),华法林OR 1.29(95%CI 1.23–1.35),低分子肝素OR 1.26(95%CI 1.20–1.32),均高于阿司匹林组。
- 与阿司匹林相比,低分子肝素血肿风险OR 1.69(95%CI 1.46–1.96),间接Xa因子抑制剂OR 1.62(95%CI 1.13–2.26),直接Xa因子抑制剂OR 1.55(95%CI 1.35–1.78),华法林OR 1.33(95%CI 1.14–1.55)。
- 阿司匹林组148,159例(32.05%),直接Xa因子抑制剂123,909例(26.80%),华法林96,338例(20.84%),低分子肝素84,962例(18.38%)。
关键数值与推荐
- 主要结局为术后90天内MUA或血肿形成。
- 采用逻辑回归比较强效抗凝药(华法林、Xa因子抑制剂、低分子肝素)与阿司匹林对照组。
临床怎么用
- 全膝关节置换术后深静脉血栓预防可优先考虑阿司匹林,以降低MUA和血肿风险,且不增加血栓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticoagulation after total knee arthroplasty (TKA) remains a balance between clot prevention and postoperative bleeding. This study aimed to analyze anticoagulant choice for deep vein thrombosis prophylaxis on rates of stiffness requiring manipulation under anesthesia (MUA) and hematoma formation after TKA. METHODS: A large national database was queried for all primary TKAs. We included patients who filled a prescription for an anticoagulant within three days before or five days after surgery. We excluded those who filled prescriptions for multiple or no anticoagulants. Logistic regression was used to compare potent anticoagulants (warfarin, Xa inhibitors, and low molecular weight heparin (LMWH)) to our control group receiving aspirin. The primary outcomes of interest were MUA or hematoma formation within 90 days postoperatively. After applying the exclusion criteria, 462,869 patients were available to review. Of those, 148,159 (32.05%) received aspirin, followed by factor Xa inhibitors (123,909 [26.80%]), warfarin (96,338 [20.84%]), and LMWH (84,962 [18.38%]). RESULTS: Using logistic regression analyses, patients receiving factor Xa inhibitors (odds ratio [OR] 1.38 [95% confidence interval (CI) 1.32 to 1.43]), indirect factor Xa inhibitors (OR 1.33, [95% CI 1.19 to 1.48]), warfarin (OR 1.29 [95% CI 1.23 to 1.35]), and LMWH (OR 1.26, [95% CI 1.20 to 1.32]) had higher rates of MUA than the aspirin cohort. Additionally, when compared to aspirin, those receiving LMWH (OR 1.69 [95% CI 1.46 to 1.96]), indirect factor Xa inhibitors (OR 1.62 [95% CI 1.13 to 2.26]), direct factor Xa inhibitors (OR 1.55 [95% CI 1.35 to 1.78]), and warfarin (OR 1.33 [95% CI 1.14 to 1.55]) were at a significantly higher risk of hematoma formation. CONCLUSIONS: The use of aspirin for deep vein thrombosis prophylaxis after TKA is associated with a significantly lower risk of undergoing MUA and hematoma formation, without increasing the clotting risk profile, than more potent anticoagulants.
引用
- Crowley B, Hollimon M, Joaquin T, et al. The Impact of Anticoagulant Choice on Rates of Manipulation Under Anesthesia, Hematoma Formation, and Venous Thromboembolic Events. J Arthroplasty. 2026. PMID: 42373147. doi:10.1016/j.arth.2026.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。